Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777751 | 1.00 | PKM (0.36) | PKMALDH1A1KMT2AMITFSOS1 | |
| SCHEMBL1229422 | 0.87 | MITF (0.46) | PKMALDH1A1KMT2AMITFSOS1 | |
| SCHEMBL5316860 | 0.83 | ALDH1A1 (0.41) | PKMALDH1A1KMT2AMITFSOS1 | |
| SCHEMBL2223253 | 0.79 | ALDH1A1 (0.37) | PKMALDH1A1KMT2AMITFSOS1 | |
| SCHEMBL5540389 | 0.79 | ALDH1A1 (0.38) | PKMALDH1A1KMT2AMITFSOS1 | |
| SCHEMBL5539609 | 0.78 | CHRM1 (0.47) | PKMALDH1A1KMT2AMITFSOS1 | |
| SCHEMBL28523272 | 0.78 | ALDH1A1 (0.42) | PKMALDH1A1KMT2AMITFSOS1 | |
| SCHEMBL28523274 | 0.78 | ALDH1A1 (0.42) | PKMALDH1A1KMT2AMITFSOS1 | |
| SCHEMBL28531344 | 0.78 | CHRM1 (0.47) | PKMALDH1A1KMT2AMITFSOS1 | |
| SCHEMBL27610397 | 0.77 | MITF (0.40) | PKMALDH1A1KMT2AMITFSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110483549-B | Preparation method of nitroimidazole pyran antituberculosis drug | 沈阳药科大学 | 2021-03-05 | — | — | CN | disclosed |
| US-20080275035-A1 | Nitroimidazole Compounds | JIRICEK JAN | 2008-11-06 | — | — | US | disclosed |
| EP-1984369-A2 | NITROIMIDAZOLE COMPOUNDS | Novartis AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007075872-A2 | NITROIMIDAZOLE COMPOUNDS | NOVARTIS AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275035-A1 | Nitroimidazole Compounds | NQO2, NQO1, MT-ND2 | PKM 484/4885ALDH1A1 927/4885KMT2A 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.